- The approvals is based on P-II UNITY-NHL trial involves assessing Ukoniq (800 mg, qd) in 69 patients with MZL who has received at least 1 prior anti-CD20 based regimen and in 117 patients with FL who received at least 2 prior systemic therapies
- Results: ORR (49% vs 50%) as assessed by IRC, CR (16% vs 3.4%), PR (33% vs 39%), DoR of FL was 11.1 mos.
- Ukoniq is the 1st oral inhibitor of PI3K delta and CK1 epsilon. Additionally, it has received BTD for MZL and ODD for MZL and FL
Click here to read full press release/ article | Ref: TG Therapeutics | Image: Seeking Alpha